2020 Department Publications (36)

Beesley VL, Webber K, Nagle CM, DeFazio A, Obermair A, Williams M, Friedlander M, Webb PM. When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer. Gynecologic Oncology. 159.1 (2020): 179-186

Read DJ, Frentzas S, Ward L, De Ieso P, Chen S, Devi V. Do histopathological features of breast cancer in Australian Indigenous women explain the survival disparity? A two decade long study in the Northern Territory. Asia‐Pacific Journal of Clinical Oncology. 2020 Dec;16(6):348-55.

Koczwara, B., Bonnamy, J., Briggs, P., Brown, B., Butow, P.N., Chan, R.J., Cohn, R.J., Girgis, A., Jefford, M., JL Joske, D., Licqurish, S., Mackay, G., Saunders, C.M. and Webber, K. (2020), Patient‐reported outcomes and personalised cancer care. Med J Aust. https://doi.org/10.5694/mja2.50893

Partelli S, Ramage J, Massironi S, Zerbi A, Kim H, Niccoli P, Panzuto F, Landoni L, Tomazic A, Ibrahim T, Kalstas G, Bertani E, Sauvanet A, Segelov E….Falconi M. Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study”” Frontiers in Medicine 2020, 7:1009

D.Day, A. Prawira, A. Spreafico, J. Waldron, M. Giuliani, I. Weinreb, J. Kim, J. Cho, A. Hope, A. Bayley, J. Ringash, S.V. Bratman, R. Jang, B. O’Sullivan, L.L. Siu, A.R. Hansen. Phase I trial of alpelisib in combination with concurrent cisplatin‐based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck. Oral Oncology  2020 Sep 1;108:104753

Fettke H*, Kwan EM*, Docanto MM, Bukczynska P, Ng N, Graham LK, Mahon K, Hauser C, Tan W, Wang XH, Zhao Z, Zheng T, Zhou K, Du P, Yu J, Yong H, Jia S, Kohli M, Horvath LG, Azad AA. Combined cell‐free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multi‐analyte liquid biopsy assay for metastatic prostate cancer. Eur Urol 2020. May 30

Fettke H, Steen J, Kwan EM, Bukczynska P, Keerthikumar S, Goode D, Docanto M, Ng N, Martelotto L, Hauser C, Southey M, Azad AA, Nguyen‐Dumont T. Analytical validation of an error‐corrected next‐generation sequencing assay for ultra‐sensitive ctDNA profiling. Biotechniques 2020. Jun;69(2):133-40

Pereira‐Salgado A, Kwan EM, Tran B, Gibbs P, De Bono J, IJzerman MJ. Systematic Review of Efficacy and Health Economic Implications of Real‐world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in? Eur Urol Focus 2020.Apr 6

Kohli M, Tan W, Zheng T, Wang A, Montesinos C, Wong C, Du P, Ji S, Yadav S, Horvath LG, Mahon K, Kwan EM, Fettke H, Yu J, Azad AA. Clinical and genomic insights into circulating tumor DNA–based alterations across the spectrum of metastatic hormone‐sensitive and castrateresistant prostate cancer. EBioMedicine 2020;54:102728.

Liow E and Tran B Precision Oncology in Urothelial cancer ESMO Open 5 Suppl (2020): e000616

Brokwell N, Alamgeer M, Kumar B, John T, Parker N. Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma , 2020 Jun;9(3):639–645

Tran B*, Vajdic CM*, Webber K*, Laaksonen MA, Stavrou EP, Tiller K, Suchy S, Bosco AM, Harris MF, Lloyd AR, Goldstein D. Self‐reported health, lifestyle and social circumstances of Australian adult cancer survivors: a propensity score weighted cross‐sectional study. Cancer Epidemiology, 2020 Aug 1;67:101773.

Davies, A., Lum, C., Raju, R., Ansell, E., Webber, K., & Segelov, E. Anti‐cancer therapy made easier: a 25‐year update. Internal Medicine Journal 2020. May 3.

Ho G, Ananda S, Vandenberg C, McNally O, Tie J, Gorringe K, Bowtell D, Pyman J, Wakefield M, Scott C Glucagonoma Masquerading as a Mucinous Cancer of the Ovary: Lessons from Cell Biology. Gynaecological Malignancies; Updates & Advances IntechOpen; 2020 May 18:51

Jung M, Gao J, Cheung L, Bongers A, Somers K, Clifton M, Ramsay E, Russell A, Valli E, Gifford A, George J, Kennedy C, Wakefield W, Topp M, Ho G, Australian Ovarian Cancer Study, Scott C, Bowtell D, DeFazio A, Norris M, Haber M, Henderson M ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer. International Journal of Cancer; 2020: Apr 10.

Singh S, Bergsland E, Card C, Hope T, Kunz P, Ladiley D, Lawrence B, Leyden S, Michael M, Modahl L, Myrehaug S, Padda S, Pommier R, Ramirez R, Soulen M, Strosberg J, Thawer A, Wei B, Xu B, Segelov E. 2020. Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus. Journal of Thoracic Oncology 11 July 2020.

Rao S, Sclafani F, Eng C, Grønlie Guren M, Adams R, Benson A, Sebag-Montefiore D, Segelov E, Bryant A, Peckitt C, Roy A. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct  J Clinical Oncology 2020 Aug 1;38(22):2510-8 and Sheela Rao and Segelov E et al Journal of Clinical Oncology Published online October 07, 2020

Symonds EL, Pedersen SK, Murray D, Byrne SE, Roy A, Karapetis C, Hollington P, Rabbitt P, Jones FS, LaPointe L, Segelov E. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer. 2020. Cancer.126 (7) 1460-1469.

Segelov E, Underhill C, Prenan H, Karapetis C, Jackson C, Nott L, Clay T, Pavlakis N, Sabesan S, Heywood E. Steer C, Lethborg C, Gan H, Yip D, Karanth N, Karikios D MacIntyre R. Practical considerations for treating cancer patients in the COVID-19 pandemic JCO Oncology Practice 10. DOI: 10.1200/OP.20.00229

Bennett S, Soreide K, Golami S, Pessaux P, Teh C, Segelov E, Kennecke H, Prenen H,   Myrehaug S, Callegaro D, Hallet J. Delaying strategies to upfront surgery for the management of resectable hepato-biliary malignancies during the COVID-19 pandemic: a rapid review Current Oncology 27:5, Oct. 2020.

Segelov E, Day D, Prenan H Lopez G, Chia J, Chong HC. Impact of the COVID-19 epidemic on a pan-Asian academic oncology clinical trial. JCO Global Oncology 2020, Published online 15 Apr 2020.

Segelov E and Garvey G. Cancer and Indigenous Populations: time to end the disparity. JCO Global Oncology, 2020:6, 80-82.

Lum C, Prenen H, Body A, Lam M, Segelov E. A 2020 Update of anal cancer: The increasing problem in women and expanding treatment landscape, Expert Review of Gastroenterology & Hepatology. 2020. Jul 2.

Lim L, Thomas D, Chan D, Wyld D, Cehic G, Macdonald W, Tincknell G, Bailey D, Kuchel A, Du T, Pavlakis N, Davis A, Segelov E. Australian experience of peptide receptor radionuclide therapy for lung neuroendocrine tumours. Oncotarget,Jul 7;11(27):2636

Lam M, Lum C, Smith S, Latham S, Prenen H, Segelov E. Refractory metastatic colorectal cancer: current challenges and future prospects. Cancer Management and Research.   2020:12 5819–5830.

Underhill C, Parente P, McArthur G, Heydon A, McLachlan S, Wong Z, Segelov E. Towards new models of cancer care in Australia: lessons from Victoria’s response in the COVID-19 pandemic. 2020: Int Med J 50:10:1286-1289

Gordon L, Elliott T, Leyden J, Pavlakis N, Michael M, Mumford J, Segelov E, Wakelin K, Wyld D. The economic impact to patients with neuroendocrine tumours. The Patient – Patient-Centered Outcomes Research. 2020. 13 (3) 363-373.

Price T, Tang M, Gibbs P, Haller D, Peeters M, Arnold D, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. 2020. Management of early stage gastro-oesophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty Expert Review of Anticancer Therapy 2020 20 (4) 305-324. 

Bourlon M, Woodruff T, Anazado A, Segelov E Oncofertility as a universal right and a Global Oncology Priority (Editorial). JCO Global Oncology 6 (2020) 314-16.

Blinman P, Martin A, Jefford M, Goldstein D, Boadle D, Morris M, Tebbutt N, Aiken C, Paul J, Segelov E, Haydon A, Iveson T, Stockler M. 2020. Patients’ preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile? JNCI Cancer Spectrum 2020 Nov 28

Wang Y; Logan S; Stern K; Wakefield C; Cohn R; Agresta F; Jayasinghe Y; Deans R; Segelov E; McLachlan R; Gerstl B; Sullivan E; Ledger W; Anazodo A. Supportive Oncofertility Care, Psychological Health and Reproductive Concerns: A Qualitative Study; Supportive Care in Cancer. 2020 Feb 1;28(2):809-17.

Clarke S, Burge M, Feeney K, Jones K, Gibbs P, Molloy M, Marx G, Price T, Reece W, Segelov E, Tebbutt N. 2018. Results from an Australian translational study to evaluate the prognostic role of inflammatory markers in patients with mCRC treated with bevacizumab [ASCENT]. PLOS One 15.3 (2020): e0229900.

Lau D, Burge M, Roy A, Chau I, Haller D, Shapiro J, Peeters M, Pavlakis N, Karapetis C, Tebbutt N, Segelov E, Price T, 2020. Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019, Expert Review of Anticancer Therapy, 2020 20:4, 251-270.

Rasschaert M, Vulsteke C, De Keersmaeker S, Dias S, Vandenborne K, Verschaeve V, Vuylsteke P, Van Brussel I, Ravelingien J, Van Dam P, Segelov E, Peeters M. AMTRA: a home-based monitoring and tailored toxicity management system in Cancer patients: a multicentered experience. Supportive Care in Cancer. (2020 June 9).

Nguyen M, Tipping-Smith S, Lam M, Liow E, Davies A, Prenen H, Segelov E,  An update on the use of immunotherapy in patients with colorectal cancer.2020. Expert Review of Gastroenterology & Hepatology 2020 Nov 9: 1-4

2020 Abstracts (34)

Segelov E, Carrington C, Aranda, S.K., Currow, D., Zalcberg, J., Heriot, A.G., Mileshkin, L., Bashford, J., Coutsouvelis, J., O’Kane, C. and Sulkowsk, A. Developing clinical indicators for Oncology: The inaugural indicator set for The Australian Council on Healthcare Standards (ACHS). 2020. Asia-Pacific Journal of Clinical Oncology 16: S8 p71

Segelov E. Practical considerations for treating cancer patients in the COVID-19 pandemic. 2020. Asia-Pacific Journal of Clinical Oncology 16: S8 p81

Segelov E, McLaren C, Liow E, Smith S, Latham S, Kong J, Lam M, Lum C, Body A, Briggs P. 2020. Systemic anticancer treatment changes at the start of the COVID-19 pandemic in a large metropolitan health service. Asia-Pacific Journal of Clinical Oncology 16: S8 p91

Lum C, Smith S, Martin K, Segelov E. Treatment outcomes in an institutional cohort of female patients with anal SCC undergoing definitive chemoradiation. 2020. Asia-Pacific Journal of Clinical Oncology 16: S8 p153

Menon S, Davies A, Frentzas S, Hawkins C, Segelov E, Day D, Markman B. Recruitment, outcomes and toxicity trends in phase 1 oncology trials: six year experience in a large institution. 2020Asia-Pacific Journal of Clinical Oncology 16: S8 p154

Segelov E, Underhill C, Prenen H, Babin R. 2020. The Oncology Journal Club Podcase- An innovative format delivering oncology education. Asia-Pacific Journal of Clinical Oncology 16:S8 p163

Davies A, Buckley D, Ragunath A, Martin K, Prenen H, Cook O, Segelov E. Patient preferences regarding oral anti-cancer therapy: A systematic review. 2020. Asia-Pacific Journal of Clinical Oncology 16: S8 p146

McLaren, C., Segelov E, and Ristevski, E., 2020. Voluntary Assisted Dying (VAD) in Victoria: An audit of timings within the application process. Asia-Pacific Journal of Clinical Oncology16(S8), pp.94-94.

McPhee N, Segelov E, Nightingale C, Harris S, Ristevski E. 2020. Access to and availability of cancer clinical trials in Victoria, 2018 Asia-Pacific Journal of Clinical Oncology 16: S8 p173

Cook O, Webber K, White M, Kwok A, Segelov E. 2020. Exploring the profile of baseline patient-reported outcome measures and patient-reported experience measures in an outpatient oncology setting. Asia-Pacific Journal of Clinical Oncology 16: S8 p200

Webber K, Cook O, White M, Kwok A, Segelov E. Real time collection and use of patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) in outpatient oncology: barriers, enablers, and impact on consultation length. 2020. Asia-Pacific Journal of Clinical Oncology 16: S8 p145.

Li FG, Deans R, Nesbitt-Hawes E, Budden AK, McCormack L, Maheux-Lacroix S, Segelov E, Lyons SD, Abbott JA. Fractionated Laser for Vaginal Atrophy Symptoms: A Randomized, Double-Blind Placebo Controlled Study. Journal of Minimally Invasive Gynecology. 2020 Nov 1;27(7):S69.

Cook O, Daiyan Y, Yeganeh L, Davies A, Kwok A, Webber K, Segelov E. Exploration of the use and impact of patient-reported experience measures (PREMs) in oncology settings: A systematic review. Journal of Clinical Oncology 38 (29_suppl), 166-166

McLaren C, Segelov E, Ristevski E. 2020. 1875P Voluntary assisted dying in Victoria, Australia: A case series. Annals of Oncology. 2020 Sep 1;31:S1068

Anaka, M., Chan, D., Pattison, S., Thawer, A., Franco, B., Moody, L., Jackson, C., Segelov E, Singh, S., Understanding the Treatment Preferences of Neuroendocrine Tumor Patients Using Discrete Choice Experiments. (2020): Pancreas 49:3 pp. 462-462.

Bourlon M, Jimenez B, Matar C, Gunn E, Ginsburg O, Lopes G, Segelov E. Global oncology authorship and access patterns. (2020): J Clin Oncol 38 (15) S:7061-7061.

Day D, Chia J, Foo M, Ali R, Toh H, Segelov E. Operational challenges of engaging the Asian Pacific (APAC) region in an academic oncology clinical trial. Annals of Oncology 2020 Nov 1;31:S1280.

Gordon L, Elliott T, Leyden J, Pavlakis N, Michael M, Mumford J, Segelov E Wakelin K, Wyld D. The Economic Impact to Patients with Neuroendocrine Tumours. 2020. Neuroendocrinology 110, 94-94.

Partelli S, Zerbi A, Massironi S, Jin-Young J, Landoni L, Van Dijkum E, Ramage J, Segelov E, Armstrong T, Niccoli P, Sauvanet A, Falconi M. Interim Analysis of Prospective Evaluation of the Management of Sporadic Nonfunctioning Asymptomatic Pancreatic Neuroendocrine Neoplasms ≤ 2 cm (ASPEN Study) 2020. Neuroendocrinology 110, 96-96

Kevin Kelly, Daniel Costin Danila, William Jeffery Edenfield, Rahul Raj Aggarwal, Daniel Peter Petrylak, A. Oliver Sartor, Christopher Joseph Sumey, Tanya B. Dorff, Evan Y. Yu, Nabil Adra, David Michael Waterhouse, Andrew J. Armstrong, Lisa Horvath, David William Pook, Leonard Joseph Appleman, Aubrey Lau, Mark Salvati, Hosein Kouros-Mehr Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). DOI: 10.1200/JCO.2020.38 suppl.TPS5589 Journal of Clinical Oncology 38,Published online May 25, 2020.

Oliver Klein, Damien Kee, Bo Gao, Ben Markman, Linda R. Mileshkin, Clare L. Scott, Yeojeong So, Richelle Linklater, Andreas Behren, Jodie Palmer, Matteo S. Carlino, Jonathan S. Cebon Combination immunotherapy with ipilimumab and nivolumab in patients with rare gynaecological malignancies DOI: Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 6091-6091.

Oliver Klein, Damien Kee, Adnan Nagrial, Ben Markman, Craig Underhill, Michael Michael, Caroline Lum, Andreas Behren, Jodie Palmer, Niall C. Tebbutt, Matteo S. Carlino, Jonathan S. Cebon Combination immunotherapy with ipilimumab and nivolumab in patients with advanced biliary tract cancers. 2020. 4588

10.1200/JCO.2020.38.15_suppl.4588 Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 4588-4588. Published online May 25, 2020.

Evaluating barriers to uptake of comprehensive genomic profiling (CGP) in advanced cancer patients (pts). Kortnye Maureen Smith, Sophie O Haire, Dong Anh Khuong-Quang, Ben Markman, Hui Kong Gan, Paul G Ekert, Kenneth John O’Byrne, Michael Millward, Benjamin J. Solomon, Ben Tran, Clare L. Scott, Damien Kee, Grant A. McArthur, Andrew Fellowes, Rona Weerasuriya, Elly Lynch, Melissa Martyn, Clara Gaff, Stephen B. Fox, Jayesh Desai DOI: 10.1200/JCO.2020.38.15_suppl.2033 Journal of Clinical Oncology 38, no.15_suppl (May 20,2020) 2033-2033. Publised online May 25, 2020.

Anaka, M., Chan, D., Pattison, S., Thawer, A., Franco, B., Moody, L., Jackson, C., Segelov E, Singh, S., Understanding the Treatment Preferences of Neuroendocrine Tumor Patients Using Discrete Choice Experiments. (2020): Pancreas 49:3 pp. 462-462.

Bourlon M, Jimenez B, Matar C, Gunn E, Ginsburg O, Lopes G, Segelov E. Global oncology authorship and access patterns. (2020): J Clin Oncol 38 (15) S:7061- 7061.

Day D, Chia J, Foo M, Ali R, Toh H, SEGELOV E. Operational challenges of engaging the Asian Pacific (APAC) region in an academic oncology clinical trial. European Society of Medical Oncology Asia Annual Meeting Oct 2020.

Gordon L, Elliott T, Leyden J, Pavlakis N, Michael M, Mumford J, Segelov E, Wakelin K, Wyld D. The Economic Impact to Patients with Neuroendocrine Tumours. 2020. Neuroendocrinology 110, 94-94.

Menon S, Davies A, Alamgeer M. Clinical outcomes in patients with locally advanced head and neck cancer (LA HNSCC) receiving Cisplatin versus non- Cisplatin chemotherapy. C linical Oncology Society of Australia 2020. Poster presentation

McPhee N, Harris S, Nightingale C. Ristevski C, Segelov E. Access to and Availability of Cancer Clinical Trials in Victoria, 2018. C linical Oncology Society of A ustralia 2020. Poster presentation

Jermaine Coward, Charlotte Rose Lemech, Anna Rachelle Mislang, Sagun Parakh, Sophia Frentzas, Craig Underhill, Adnan Nagrial, Xiaoping Jin, Baiyong Li, Zhongmin Maxwell Wang, Kon Yew Kwek, Dennis Xia. A Phase I Study of AK112, a Bispecific Antibody that Targets PD-1 and VEGF Co-expressing T cells, in Patients with Advanced Solid Tumours, 27971, ASCO 2020

Xichun Hum Jian Zhang, Leiping Wang, Sara Hurvitz, Janice Lu, Catherine Shannon, Katherine Cuff, Sophia Frentzas, Gang  Xia, Yangping Ji et al. Randomised, multicentre, open-label Phase II/III study of ARX788 vs lapatinib and Capecitabine in patients with Her2-positive locally advanced or metastatic breast cancer (ZMC-ARX788-211), SARCS Dec 2020

Durm, Gregory, Sophia Fretzas, Erik Rasmussen, Saltanat Najmi and Nooshin Sadraei. “417 Design and rationale of a phase 1 study evaluating AMG 256, a novel targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors.” (2020)

Brockwell NK, Alamgeer M, Kumar B, Rivalland G G, John T, Parker BS, Preliminary study highlights the potential of immune checkpoint inhibitors in scarcomatoid mesothelioma. translational lung cancer research. 2020 Jun;(3):639.

Book Chapters and Books (3)

A Better Death (Simon & Schuster) R.Srivastava

Ho G, Frentzas S. Gynaecological Malignancies; Updates & Advances – BoD–Books on Demand; 2020 Jun 17

Sophia Frentzas. Caroline Lum, Ting-Yu Chen. Anglogenesis and its Role in the Tumour Microenvironment: A target for Cancer Therapy. IntechOpen. April 2020

Book your COVID-19 vaccination -Find out more
+